Sorted By:

Relevance


ICYMI: Wall Street Journal and Washington Post Say TPP Should Protect Medical Innovation

PhRMA  |  Blog Post

Such protections are essential to modern industries, from biotech and software to movies and music, that are particular strengths of America’s innovative, knowledge-based economy.”
http://catalyst.phrma.org/icymi-wsj-and-washington-post-say-tpp-should-protect-medical-innovation

Burden on Patients: Access to Asthma Medicine and the Risk of Going Without

PhRMA  |  Blog Post

Be sure to follow our series on The Catalyst, Twitter and Facebook and take a look at our new .phrma.org/fact-sheets?
http://catalyst.phrma.org/burden-on-patients-access-to-asthma-medicine-and-the-risk-of-going-without

Milliman Report: Reducing Part D Beneficiary Costs through Point-of-Sale Rebates

PhRMA  |  Report

PhRMA engaged Milliman to assess the impact of changing pharmacy and manufacturer rebates to the POS.
https://www.phrma.org/report/reducing-part-d-beneficiary-costs-through-point-of-sale-rebates

Partnership for Prescription Assistance Adds New Feature to Website to Help America’s Uninsured Access Information about Medicaid and CHIP

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.
https://www.phrma.org/press-release/partnership-for-prescription-assistance-adds-new-feature-to-website-to-help-america-s-uninsured-access-information-about-medicaid-and-chip

Director – Federal Advocacy

PhRMA  |  PhRMA Career

We are committed to the growth and development of our team members and offer many learning opportunities such as tuition reimbursement at both the undergraduate and graduate levels, industry on-site and off-site training, PhRMAcademy lunch and learn sessions, presentation skills, performance management and other management/professional develop programs. 
https://www.phrma.org

Policy Solutions to Foster Innovation and Access to Personalized Medicines: Development

Chartpack  |  From Our Network

Policies must ensure a clear and transparent regulatory framework for the development of personalized medicine technologies, and work to capture larger and more diverse forms of data.
http://chartpack.phrma.org/personal-medicines-in-development-chartpack/advancing-policies-to-foster-innovation-sustaining-advances-in-personalized-medicine/policy-solutions-to-foster-innovation-and-access-to-personalized-medicines-development

Medicines Account for a Small Share of Health Spending Differences Between the United States and Other Countries

Chartpack  |  From Our Network

...
http://chartpack.phrma.org/2016-perspective/chapter-5/medicines-account-for-a-small-share-of-health-spending-differences-between-the-united-states-and-other-countries

Intellectual Property

PhRMA  |  From PhRMA

Nations like the United States, Japan, and some European nations enjoy strong, modern approaches to intellectual property that encourage investment and innovation.
https://www.phrma.org/advocacy/intellectual-property

Medicines Account for a Small Share of Health Spending Differences Between the United States and Other Countries

Chartpack  |  From Our Network

Medicines account for a small share of health spending differences between the United States, Canada and Germany.
http://chartpack.phrma.org/biophrma-chartpack/spending-and-costs/medicines-account-for-a-small-share-of-health-spending-differences-between-the-united-states-and-other-countries

Diabetes: Innovation Improves Care & Reduces Costs

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/innovation-and-adherence-improves-care-and-reduces-costs-diabetes

New PhRMA Report: Nearly 200 medicines in development for heart disease, stroke and other cardiovascular diseases

PhRMA  |  Blog Post

To help drive that process, ABC established a Clinical Trials Network (CTN) that matches investigators with trials and helps recruit and retain African American patients for participation.
http://catalyst.phrma.org/new-phrma-report-medicines-in-development-for-heart-disease-stroke-2015

Medicare Monday: Gaining Part D Coverage Reduces Hospitalizations and Overall Spending in Medicare

PhRMA  |  Blog Post

We encourage you to check back often and follow the #MedicareMonday hashtag for more!
http://catalyst.phrma.org/medicare-monday-gaining-part-d-coverage-reduces-hospitalizations

Fact Check Friday: The Truth about IPR and Biopharmaceutical Patents

PhRMA  |  Blog Post

This will help safeguard investments in the next generation of treatments and cures for America’s patients. 
http://catalyst.phrma.org/fact-check-friday-july-31-2015

Medicare Monday: What a one-size-fits-all treatment means for arthritis patients and quality of life

PhRMA  |  Blog Post

Download Mary’s profile as a PDF, and sign up for regular updates here.
http://catalyst.phrma.org/medicare-monday-what-a-one-size-fits-all-treatment-means-for-arthritis-patients-and-quality-of-life

From Discovery Through Delivery, Policies Must Foster Continued Innovation and Patient Access to Personalized Medicines

Chartpack  |  From Our Network

At a time when the scientific promise is greater than ever, thoughtful policies are necessary to accelerate advances in targeted therapy for patients. ...
http://chartpack.phrma.org/personal-medicines-in-development-chartpack/advancing-policies-to-foster-innovation-sustaining-advances-in-personalized-medicine/from-discovery-through-delivery-policies-must-foster-continued-innovation-and-patient-access-to-personalized-medici

Policies Are Essential in Fostering Future Growth of the US Biopharmaceutical Industry and Its Ability to Innovate

Chartpack  |  From Our Network

Industry analysts have identified that strength in coverage and payment policies, intellectual property protections and the regulatory system are essential to future growth in the biopharmaceutical industry. 
http://chartpack.phrma.org/biophrma-chartpack/economic-impact/policies-are-essential-in-fostering-future-growth-of-the-us-biopharmaceutical-industry-and-its-ability-to-innovate

Comments of the Pharmaceutical Research and Manufacturers of America on the PTO’s Request for Comments on Amendments to the Rules of Practice for Trials Before the Patent Trial and Appeal Board

PhRMA  |  Speeches & Communication

The U.S. biopharmaceutical sector supports a total of 3.4 million jobs throughout the economy, and directly employs more than 810,000 Americans.
https://www.phrma.org/public-communication/comments-of-the-pharmaceutical-research-and-manufacturers-of-america-on-the-pto-s-request-for-comments-on-amendments-to-the-rules-of-practice-for-trials-before-the-patent-trial-and-appeal-board

Modernizing Drug Discovery, Development & Approval

PhRMA  |  Report

Against this backdrop, pro-patient, pro-science, pro-market reforms at the Food and Drug Administration (FDA) would enhance the competitive market for biopharmaceuticals, drive efficiency in drug development and discovery and help hold down costs.
https://www.phrma.org/report/policy-solutions-modernizing-drug-discovery-development-and-approval

Medicare Monday Then & Now: Beneficiary Premiums

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/medicare-monday-then-and-now-beneficiary-premiums

Innovation Spotlight: What is the Future of Health Care?

PhRMA  |  Video

Speakers from the event included Arianna Huffington, entrepreneur and founder of the health website ThriveGlobal, Aneesh Chopra, the first chief technology officer of the United States, Steven Corwin, M.D., CEO of New York-Presbyterian Hospital and PhRMA president and CEO Stephen Ubl.
https://www.phrma.org

Patient Groups, Members of Congress and Other State-Based Stakeholders Agree: Stop the Abuse of Biopharmaceutical Patents

PhRMA  |  Blog Post

America’s patients depend on stopping the abuse of biopharmaceutical patents and that’s why the Epilepsy Foundation and more than 90 national and state-based advocacy organizations sent a letter to the House and Senate Judiciary Committees on May 21 urging Congress to enact legislative reforms that maintain an effective patent system.
http://catalyst.phrma.org/patient-groups-members-of-congress-and-other-state-based-stakeholders-agree-stop-the-abuse-of-biopharmaceutical-patents

Study highlights negative impact of Canada's promise doctrine on R and D investment

PhRMA  |  Blog Post

For more information on Canada’s promise doctrine and its overall approach to IP, go to PatentsProtect.org.
http://catalyst.phrma.org/study-highlights-negative-impact-of-canadas-promise-doctrine-on-rd-investment

Clarity around anti-kickback statute needed to promote innovative payment arrangements

PhRMA  |  Blog Post

Providing clear safe harbor protection to RBCs can encourage the uptake of these innovative payment arrangements and help advance our movement toward a health care system that better recognizes value.
http://catalyst.phrma.org/clarity-around-anti-kickback-statute

HIV/AIDS: Then & Now

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/hiv/aids-then-and-now1

Higher deductibles and more dissatisfaction with health plans according to new poll

PhRMA  |  Blog Post

Learn more about this and other solutions here.
http://catalyst.phrma.org/new-poll-finds-less-satisfaction-with-coverage-due-to-rising-deductibles

You have reviewed the first 400 results out of 2501. Each page contains 25 results. You're on page 16.

prev 13 14 15 16 17 18 next